Plasma catecholamine concentration in hypertensive subjects with chronic renal failure before and during treatment with the beta-receptor blocking drug metipranolol.
In seven male hypertensive patients with chronic renal failure (serum creatinine level 6.9 +/- 4.1 mg%) plasma catecholamine levels were in the same range as in five normotensive healthy volunteers. Treatment with the beta-receptor blocker metipranolol (2 x 20 mg/day orally for 2 weeks) significantly elevated plasma catecholamine levels in the hypertensive patients with chronic renal failure, but not in the healthy volunteers. Blood pressure and heart rate were reduced in both groups.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002395:Catecholamines / Q000097:blood*; D003404:Creatinine / Q000097:blood; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006977:Hypertension, Renal / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood*; D008297:Male; D014290:Metipranolol / Q000627:therapeutic use*; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D011412:Propanolamines / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D011412:Propanolamines; D003404:Creatinine; D014290:Metipranolol; D009638:Norepinephrine